Table 1: JAK inhibitors approved and in development

From: The emerging safety profile of JAK inhibitors in rheumatic disease

CompoundTargetIndicationStage of development
ABT-494JAK1RAPhase I
Crohn's diseasePhase II
Ulcerative colitisPhase II
Atopic dermatitisPhase I
BaricitinibJAK1, JAK2RAPhase III
PsoriasisPhase II
Diabetic nephropathyPhase II
SLEPhase II
Atopic dermatitisPhase II
DecernotinibJAK3RAPhase II (development currently on hold)
CYT387JAK1, JAK2MyelofibrosisPhase I–II
FilgotinibJAK1RAPhase III
Crohn's diseasePhase III
Ulcerative colitisPhase III
INCB018424JAK1, JAK2Psoriasis (topical treatment)Phase II
PacritinibJAK2MyelofibrosisPhase II
PeficitinibJAK1, JAK3RAPhase III
PsoriasisPhase II
RuxolitinibJAK1, JAK2MyelofibrosisApproved by FDA
TofacitinibJAK1, JAK3RAApproved by FDA
PsoriasisPhase III
Ulcerative colitisPhase III ongoing
JIAPhase I
  1. JAK, Janus kinase; JIA, juvenile idiopathic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.